Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Released Its Half-Year Earnings: Here's What Analysts Think
Investors in Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) had a good week, as its shares rose 8.6% to close at €58.80 following the release of its half-yearly results. Results overall were respectable, with statutory earnings of €2.75 per share roughly in line with what the analysts had forecast. Revenues of €344m came in 4.1% ahead of analyst predictions. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Taking into account the latest results, Laboratorios Farmaceuticos Rovi's eight analysts currently expect revenues in 2026 to be €771.7m, approximately in line with the last 12 months. Statutory earnings per share are expected to crater 23% to €2.80 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of €770.2m and earnings per share (EPS) of €2.59 in 2026. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.
See our latest analysis for Laboratorios Farmaceuticos Rovi
The consensus price target was unchanged at €74.36, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Laboratorios Farmaceuticos Rovi analyst has a price target of €83.00 per share, while the most pessimistic values it at €64.20. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Laboratorios Farmaceuticos Rovi's past performance and to peers in the same industry. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 0.4% by the end of 2026. This indicates a significant reduction from annual growth of 3.1% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 8.5% per year. It's pretty clear that Laboratorios Farmaceuticos Rovi's revenues are expected to perform substantially worse than the wider industry.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Laboratorios Farmaceuticos Rovi following these results. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Laboratorios Farmaceuticos Rovi's revenue is expected to perform worse than the wider industry. The consensus price target held steady at €74.36, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Laboratorios Farmaceuticos Rovi analysts - going out to 2028, and you can see them free on our platform here.
Before you take the next step you should know about the 2 warning signs for Laboratorios Farmaceuticos Rovi that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.